Wellington Management Group LLP Has $18.73 Million Holdings in Xeris Biopharma Holdings, Inc. $XERS

Wellington Management Group LLP increased its position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 8.9% in the second quarter, Holdings Channel.com reports. The institutional investor owned 2,365,103 shares of the company’s stock after buying an additional 193,749 shares during the period. Wellington Management Group LLP’s holdings in Xeris Biopharma were worth $18,732,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. BlackRock Inc. bought a new stake in Xeris Biopharma during the second quarter valued at $115,042,000. Vanguard Group Inc. raised its position in shares of Xeris Biopharma by 13.8% in the 4th quarter. Vanguard Group Inc. now owns 11,186,677 shares of the company’s stock worth $87,815,000 after acquiring an additional 1,358,760 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Xeris Biopharma by 3.3% in the 4th quarter. Geode Capital Management LLC now owns 4,275,989 shares of the company’s stock valued at $33,571,000 after purchasing an additional 135,815 shares during the period. State Street Corp lifted its stake in shares of Xeris Biopharma by 10.1% in the 4th quarter. State Street Corp now owns 4,116,924 shares of the company’s stock valued at $32,318,000 after purchasing an additional 378,595 shares during the period. Finally, Qube Research & Technologies Ltd lifted its stake in shares of Xeris Biopharma by 6.0% in the 3rd quarter. Qube Research & Technologies Ltd now owns 3,274,834 shares of the company’s stock valued at $26,657,000 after purchasing an additional 185,063 shares during the period. Institutional investors and hedge funds own 42.75% of the company’s stock.

Xeris Biopharma Price Performance

XERS stock opened at $8.53 on Monday. The stock has a market capitalization of $1.56 billion, a PE ratio of -77.55 and a beta of 0.70. The company’s 50-day moving average is $8.41 and its 200-day moving average is $6.98. The company has a debt-to-equity ratio of 17.00, a current ratio of 1.45 and a quick ratio of 1.02. Xeris Biopharma Holdings, Inc. has a 1 year low of $5.25 and a 1 year high of $10.08.

Xeris Biopharma (NASDAQ:XERS) last issued its earnings results on Thursday, August 6th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.19). Xeris Biopharma had a negative net margin of 5.12% and a positive return on equity of 338.21%. The firm had revenue of $92.10 million during the quarter, compared to the consensus estimate of $90.12 million. Equities research analysts expect that Xeris Biopharma Holdings, Inc. will post 0.07 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently commented on XERS shares. Barclays raised their target price on Xeris Biopharma from $9.00 to $12.00 and gave the stock an “overweight” rating in a research note on Thursday, August 20th. Wall Street Zen cut Xeris Biopharma from a “buy” rating to a “hold” rating in a report on Saturday. Finally, Weiss Ratings downgraded shares of Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Three equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Xeris Biopharma presently has an average rating of “Hold” and a consensus price target of $12.00.

Insider Buying and Selling at Xeris Biopharma

In other news, insider Beth Hecht sold 16,666 shares of the company’s stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $8.49, for a total transaction of $141,494.34. Following the transaction, the insider directly owned 1,127,796 shares of the company’s stock, valued at $9,574,988.04. This represents a 1.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Steven Pieper sold 5,000 shares of the stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $8.50, for a total value of $42,500.00. Following the completion of the transaction, the insider owned 1,356,053 shares in the company, valued at approximately $11,526,450.50. This represents a 0.37% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 224,998 shares of company stock valued at $1,847,219. Company insiders own 4.35% of the company’s stock.

Xeris Biopharma Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.